16-68823404-G-C
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_004360.5(CDH1):c.1942G>C(p.Glu648Gln) variant causes a missense change. The variant allele was found at a frequency of 0.00000249 in 1,608,964 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_004360.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CDH1 | NM_004360.5 | c.1942G>C | p.Glu648Gln | missense_variant | Exon 13 of 16 | ENST00000261769.10 | NP_004351.1 | |
CDH1 | NM_001317184.2 | c.1759G>C | p.Glu587Gln | missense_variant | Exon 12 of 15 | NP_001304113.1 | ||
CDH1 | NM_001317185.2 | c.394G>C | p.Glu132Gln | missense_variant | Exon 13 of 16 | NP_001304114.1 | ||
CDH1 | NM_001317186.2 | c.-24G>C | 5_prime_UTR_variant | Exon 12 of 15 | NP_001304115.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152038Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251240Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135818
GnomAD4 exome AF: 6.86e-7 AC: 1AN: 1456926Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 725240
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152038Hom.: 0 Cov.: 31 AF XY: 0.0000269 AC XY: 2AN XY: 74262
ClinVar
Submissions by phenotype
not provided Uncertain:1
This variant is denoted CDH1 c.1942G>C at the cDNA level, p.Glu648Gln (E648Q) at the protein level, and results in the change of a Glutamic Acid to a Glutamine (GAA>CAA). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. CDH1 Glu648Gln was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Glutamic Acid and Glutamine differ in some properties, this is considered a semi-conservative amino acid substitution. CDH1 Glu648Gln occurs at a position where amino acids with properties similar to Glutamic Acid are tolerated across species and is located within the cadherin 5 domain (Brooks-Wilson 2004, Figueiredo 2013). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available evidence, it is unclear whether CDH1 Glu648Gln is a pathogenic or benign variant. We consider it to be a variant of uncertain significance. -
Hereditary diffuse gastric adenocarcinoma Uncertain:1
This sequence change replaces glutamic acid, which is acidic and polar, with glutamine, which is neutral and polar, at codon 648 of the CDH1 protein (p.Glu648Gln). This variant is present in population databases (no rsID available, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with CDH1-related conditions. ClinVar contains an entry for this variant (Variation ID: 422728). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Hereditary cancer-predisposing syndrome Uncertain:1
The p.E648Q variant (also known as c.1942G>C), located in coding exon 13 of the CDH1 gene, results from a G to C substitution at nucleotide position 1942. The glutamic acid at codon 648 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at